Contact Information: For further information contact: David Carey Lazar Partners Ltd. (646) 239-6231
Electro-Optical Sciences Announces MelaFind(R) Development Update
| Source: Electro Optical Sciences
IRVINGTON, NY--(Marketwire - January 9, 2008) - Electro-Optical Sciences, Inc. ("EOS")
(NASDAQ : MELA ), today announced that the blinded pivotal trial of
MelaFind®, a non-invasive, point-of-care instrument to assist in the
early diagnosis of melanoma, is over two-thirds complete. Six pivotal
trial study sites are currently active, and an additional seventh and final
site is expected to be activated in the upcoming weeks.
"We are very pleased with our accomplishments in 2007 including progress in
our pivotal trial and optimizing manufacturing methods to support
commercial scale capability," said Joseph V. Gulfo, MD, MBA, President &
CEO of EOS. "Looking ahead, our near-term milestones include completion of
the MelaFind® pivotal trial, analysis of trial results, and submission to
the U.S. Food and Drug Administration of our Premarket Approval (PMA)
filing which we have targeted for mid-2008."
Dr. Gulfo will present today at the 10th Annual Needham Growth Stock
Conference at 10:00am ET. To access the live webcast of this presentation
visit www.eosciences.com.
About Electro-Optical Sciences
EOS is a medical device company focused on designing and developing a
non-invasive, point-of-care instrument to assist in the early diagnosis of
melanoma. MelaFind®, EOS's flagship product, features a hand-held imaging
device that emits light of multiple wavelengths to capture images of
suspicious pigmented skin lesions and extract data. Using sophisticated
algorithms, the data are then analyzed against a proprietary database of
melanomas and benign lesions in order to provide information to the
physician and produce a recommendation of whether the lesion should be
biopsied.
Melanoma is the deadliest of skin cancers, responsible for approximately
80% of all skin cancer deaths. Unless melanoma is detected early and
excised with proper margins, the patient survival rate is poor, as there is
currently no cure for advanced stage melanoma.
For more information on EOS, visit www.eosciences.com.
Safe Harbor
This press release includes "forward-looking statements" within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes" and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory
factors.